Tirzepatide 12 mg PeptideSciences

Tirzepatide description and price

Tirzepatide was developed specifically for the treatment of type II diabetes. However, this drug also actively protects the cardiovascular system and has shown high efficacy as a weight loss agent.

Tirzepatide is a synthetic substance which is derived from gastric inhibitory polypeptide (GIP), which also has the functionality of glucagon-like peptide-1 (GLP-1). Due to this combination, tirzepatide can lower blood glucose levels, increase insulin sensitivity, and increase the feeling of satiety, which contributes to weight loss.

Tirzepatide buy online

Tirzepatide, consisting of 39 amino acids, is a synthetic analog of gastric inhibitory polypeptide (GIP). It promotes the release of insulin from the pancreas by binding to GIP and GLP-1 receptors. Long-term use of tirzepatide leads to a 26% increase in adiponectin levels. Studies have shown that tirzepatide reduces insulin levels and increases insulin sensitivity, reduces hunger, which leads to improved glucose tolerance, reduced cardiovascular risks, decreased adipose tissue, and weight loss of up to 11 kg.

What does Tirzepatide do 

Tirzepatide activates the release of insulin from the pancreas, which improves glucose control. After 6 months of use, this peptide reduces hemoglobin A1c (HbA1c) levels by 2.4% in people with type II diabetes. It also helps lose up to 11 kg of excess weight, demonstrating a dose-dependent effect.

Tirzepatide not only increases insulin release. Importantly, it significantly improves the function of the pancreatic beta cells responsible for insulin synthesis and secretion. Beta cells become more efficient in processing insulin, which leads to an increase in its level in the blood, and the load on the beta cells themselves decreases, which can slow the progression of type II diabetes.

How Tirzepatide works

Tirzepatide is administered by subcutaneous injection once a week, with an initial dose of 0.5-1 mg. The dosage is gradually increased over 4-20 weeks to reach the target dose of 5 mg, 10 mg, or 15 mg once a week. The maximum possible dose of this polypeptide is 15 mg once a week.

Tirzepatide activates the receptors for the hormones GIP and GLP-1, which are released from the intestine. Due to this, appetite decreases and, accordingly, meals are less frequent.

Tirzepatide is more effective than the strict GLP-1 agonists already approved for the treatment of type II diabetes.

Gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide, is naturally synthesized in the small intestine. Tirzepatide binds to the GIP receptor, and in doing so, simultaneously inhibits the release of gastric acid and stimulates the release of insulin. Insulin release is the main function of the GIP-R receptor and the main reason for the increase in insulin levels after a meal.

GLP-1R receptors are present on beta cells and neurons in the human brain. GLP-1R stimulation works in two ways: it activates insulin release by beta cells and reduces appetite by brain command.

Thanks to the combination of GIPR and GLP-1R, Tirzepatide gains a significant advantage over strict GLP-1R agonists. Tirzepatide acts in the same way as GIP, but it promotes the formation of cAMP, while when acting on GLP-1R, it recruits β-arrestin. As a result, Tirzepatide, when compared to endogenous GLP-1 or other synthetic agonists, leads to an increase in GLP-1R activity. This means that Tirzepatide significantly increases insulin secretion, stops inflammatory processes in adipose tissue, and reduces hunger. This combined effect makes this peptide very effective in the treatment of type II diabetes.

By increasing the amount of fat burning peptides, Tirzepatide also changes the amount of adiponectin. With elevated levels of adiponectin, the differentiation of fat cells decreases and energy expenditure increases, making mitochondria less efficient. A small amount of this peptide hormone is a consequence of such diseases as type II diabetes, atherosclerosis, and non-alcoholic fatty liver disease. 

When adiponectin levels increase, insulin sensitivity increases. This is probably why Tirzepatide regulates insulin sensitivity by several mechanisms.

Tirzepatide and hunger

At the initial stage of taking Tirzepatide, gastric emptying is delayed. Over time, this effect of the peptide becomes less pronounced due to tachyphylaxis. This effect is quite similar to that observed with pure GLP-1R agonists. This suggests that this effect of Tirzepatide is controlled by GLP-1 activity rather than GIP.

Most likely, if Tirzepatide is taken in a low dosage for a month and then gradually increased, this effect of the peptide on gastric emptying can be prolonged.

Using this regimen will also help mitigate the side effects of the drug. Due to the slower gastric emptying, the feeling of satiety lasts longer, and therefore, the craving for food becomes less. This feature of Tirzepatide, together with its ability to influence the amount of glucose, can help build a proper diet.

A brief conclusion about Tirzepatide

Tirzepatide is a synthetic peptide derived from gastric inhibitory polypeptide (GIP) that simultaneously has the functionality of glucagon-like peptide-1 (GLP-1). Due to this combination, Tirzepatide is able to reduce blood glucose, increase insulin sensitivity, and suppress hunger, thereby accelerating weight loss. Tirzepatide was developed for the treatment of type II diabetes, but it also has the ability to protect the cardiovascular system and is a powerful weight loss agent.